. Serum levels of MMP3 could be used as a potential biomarker for sports induced knee osteoarthritis
Serum levels of MMP3 could be used as a potential biomarker
Abstract
Aim: Evaluating the serum concentrations of MMP3 may serve as a promising biomarker for the diagnosis of knee osteoarthritis caused by sports activities.
Material and Methods: we identified 50 eligible participants for our research who had not had any other knee procedures apart from meniscus removal. For the determination of serum MMP-3 levels, blood was taken from 50 eligible individuals using 3 simple 6 mL EDTA vacutainer tubes. Patients also had knee aspirations, both surgical and non-surgical. Out of the 25 attempts, a successful knee synovial fluid aspirate was obtained. Additionally, all 25 attempts to get a contralateral control knee aspirate were successful. The raw values of the cohorts' demographics, radiological, clinical, PROMs, and biomarkers.
Results: The duration of pain was 4.52±0.85 and 5.85±1.22 in non-operated and operated individuals, respectively. The VSA Pain score was 48.74±2.87 and 53.55±3.39, and the Lequesne algo functional index was 11.02±1.29 and 13.36±1.57 in non-operated and operated participants, respectively. We conducted a comparative analysis of MMP-3 and GAG levels in the knees of 25 patients who had successful bilateral knee synovial fluid aspirations, comparing the operated and non-operated knees. A comparative examination of MMP-3 levels in the synovial fluid shown that, despite the considerable time elapsed after the operation, the levels of MMP3 remain notably elevated in the operated knee (p = 0.01) . Additionally, the levels of synovial GAGs in the operated joint were dramatically reduced (p = 0.03) . An inverse connection was seen between the levels of MMP-3 and GAGs in the synovial fluid when analysing all 50 samples from both operated and non-operated knees. The correlation coefficient (r) was -0.88, indicating a strong negative relationship. The p-value was 0.04, suggesting statistical significance.
Conclusions: Our results suggest that MMP3 serum levels may be a simple blood test away from becoming a diagnostic tool for knee osteoarthritis and a possible predictor of the disease. To better assess athletes' joint health, it may be helpful to combine biomarkers with other diagnostic tools and have a comprehensive understanding of their athletic background.
References
1. Mobasheri A. Osteoarthritis year 2012 in review: biomarkers. Osteoarthr Cartil. 2012;20(12):1451-64. doi: 10.1016/j.joca.2012.07.009, PMID 22842200.
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95. doi: 10.1067/mcp.2001.113989, PMID 11240971.
3. Mobasheri A. Biomarkers of osteoarthritis: translating information from in vitro culture systems to human patients. BMC Genomics. 2014;15(S2):O16. doi: 10.1186/1471-2164-15-S2-O16.
4. Eckstein F, Guermazi A, Gold G, Duryea J, Hellio Le Graverand MP, Wirth W, et al. Imaging of cartilage and bone: promises and pitfalls in clinical trials of osteoarthritis. Osteoarthr Cartil. 2014;22(10):1516-32. doi: 10.1016/j.joca.2014.06.023, PMID 25278061.
5. Sakellariou G, Conaghan PG, Zhang W, Bijlsma JWJ, Boyesen P, D’Agostino MA, et al. EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis. Ann Rheum Dis. 2017;76(9):1484-94. doi: 10.1136/annrheumdis-2016-210815, PMID 28389554.
6. Roemer FW, Kwoh CK, Hayashi D, Felson DT, Guermazi A. The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA. Nat Rev Rheumatol. 2018;14(6):372-80. doi: 10.1038/s41584-018-0010-z, PMID 29752462.
7. Guermazi A, Roemer FW, Burstein D, Hayashi D. Why radiography should no longer be considered a surrogate outcome measure for longitudinal assessment of cartilage in knee osteoarthritis. Arthritis Res Ther. 2011;13(6):247. doi: 10.1186/ar3488, PMID 22136179.
8. Guermazi A. Osteoarthritis: you can rely on radiography when managing OA, but not too much! Nat Rev Rheumatol. 2017;13(7):394-6. doi: 10.1038/nrrheum.2017.77, PMID 28541298.
9. Van Spil WE, Kubassova O, Boesen M, Bay-Jensen AC, Mobasheri A. Osteoarthritis phenotypes and novel therapeutic targets. Biochem Pharmacol. 2019;165:41-8. doi: 10.1016/j.bcp.2019.02.037, PMID 30831073.
10. Emery CA, Whittaker JL, Mahmoudian A, Lohmander LS, Roos EM, Bennell KL, et al. Establishing outcome measures in early knee osteoarthritis. Nat Rev Rheumatol. 2019;15(7):438-48. doi: 10.1038/s41584-019-0237-3, PMID 31201386.
11. Lotz M, Martel-Pelletier J, Christiansen C, Brandi ML, Bruyère O, Chapurlat R, et al. Republished: value of biomarkers in osteoarthritis: current status and perspectives. Postgrad Med J. 2014;90(1061):171-8. doi: 10.1136/postgradmedj-2013-203726rep, PMID 24534711.
12. Nguyen LT, Sharma AR, Chakraborty C, Saibaba B, Ahn ME, Lee SS. Review of prospects of biological fluid biomarkers in osteoarthritis. Int J Mol Sci. 2017;18(3):601. doi: 10.3390/ijms18030601, PMID 28287489.
13. Mobasheri A, Saarakkala S, Finnilä M, Karsdal MA, Bay-Jensen AC, van Spil WE. Recent advances in understanding the phenotypes of osteoarthritis. F1000Res. 2019;8:F1000. doi: 10.12688/f1000research.20575.1, PMID 31885861.
14. Luyten FP, Bierma-Zeinstra S, Dell’Accio F, Kraus VB, Nakata K, Sekiya I, et al. Toward classification criteria for early osteoarthritis of the knee. Semin Arthritis Rheum. 2018;47(4):457-63. doi: 10.1016/j.semarthrit.2017.08.006, PMID 28917712.
15. Kraus VB. Preclinical and early osteoarthritis. Rheumatology. 7th ed. Philadelphia: Elsevier; 2018. p. 1576-81.
16. van Spil WE, DeGroot J, Lems WF, Oostveen JC, Lafeber FP. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthr Cartil. 2010;18(5):605-12. doi: 10.1016/j.joca.2010.01.012, PMID 20175979.
17. Mobasheri A, van Spil WE, Budd E, Uzieliene I, Bernotiene E, Bay-Jensen AC, et al. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes. Curr Opin Rheumatol. 2019;31(1):80-9. doi: 10.1097/BOR.0000000000000567, PMID 30461544.
18. Bay-Jensen AC, Thudium CS, Mobasheri A. Development and use of biochemical markers in osteoarthritis: current update. Curr Opin Rheumatol. 2018;30(1):121-8. doi: 10.1097/BOR.0000000000000467, PMID 29040157.
19. van Spil WE, Szilagyi IA. Osteoarthritis year in review 2019: biomarkers (biochemical markers). Osteoarthritis Cartilage. 2020;28(3):296-315. doi: 10.1016/j.joca.2019.11.007, PMID 31887390.
20. Pengas I, Eldridge S, Assiotis A, McNicholas M, Mendes JE, Laver L. MMP-3 in the peripheral serum as a biomarker of knee osteoarthritis, 40 years after open total knee meniscectomy. J Exp Orthop. 2018 Jun 15;5(1):21. doi: 10.1186/s40634-018-0132-x, PMID 29904905, PMCID PMC6003895.
21. Ishibashi K, Sasaki E, Ota S, Chiba D, Yamamoto Y, Tsuda E et al. Detection of synovitis in early knee osteoarthritis by MRI and serum biomarkers in Japanese general population. Sci Rep. 2020;10(1):12310. doi: 10.1038/s41598-020-69328-w, PMID 32704147.
22. Ishibashi K, Sasaki E, Chiba D, Oyama T, Ota S, Ishibashi H et al. Effusion detected by ultrasonography and overweight may predict the risk of knee osteoarthritis in females with early knee osteoarthritis: a retrospective analysis of Iwaki cohort data. BMC Musculoskelet Disord. 2022;23(1):1021. doi: 10.1186/s12891-022-05989-0, PMID 36443725.
23. Sasaki E, Yamamoto H, Asari T, Matsuta R, Ota S, Kimura Y et al. Metabolomics with severity of radiographic knee osteoarthritis and early phase synovitis in middle-aged women from the Iwaki Health Promotion Project: a cross-sectional study. Arthritis Res Ther. 2022;24(1):145. doi: 10.1186/s13075-022-02830-w, PMID 35710532.
24. Ishibashi K, Sasaki E, Ota S, Oyama T, Chiba D, Yamamoto Y et al. Bone marrow lesion severity was associated with proximal tibial inclination in early knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2022;30(2):668-79. doi: 10.1007/s00167-020-06378-7, PMID 33394079.
25. Georgiev T, Ivanova M, Velikova T, Stoilov R. Serum levels of matrix metalloproteinase-3 as a prognostic marker for progression of cartilage injury in patients with knee osteoarthritis. Acta Reumatol Port. 2020;45(3):207-13. PMID 33139684.
26. Cao J, Liu Z, Zhang L, Li J. miR-940 regulates the inflammatory response of chondrocytes by targeting MyD88 in osteoarthritis. Mol Cell Biochem. 2019;461(1-2):183-93. doi: 10.1007/s11010-019-03601-z, PMID 31435813.
27. Prodanovic SZ, Radunovic G, Babic D, Ristic B, Sefik-Bukilica M, Zlatanovic M, et al. Matrix Metalloproteinases-3 baseline serum levels in early rheumatoid arthritis patients without initial radiographic changes: A two-year ultrasonographic study. Med Princ Pract. 2018;27(4):378-86. doi: 10.1159/000490350, PMID 29794470.
28. Azukizawa M, Ito H, Nishitani K, Murata K, Okahata A, Tomizawa T et al. AB1335 Serum mmp-3 is closely related to knee joint symptoms in rheumatoid arthritis patients: a cross-sectional study from kurama cohort. Ann Rheum Dis. 2018;77:1756.3-1757. doi: 10.1136/annrheumdis-2018-eular.5044.
29. Tong Z, Liu Y, Chen B, Yan L, Hao D. Association between MMP3 and TIMP3 polymorphisms and risk of osteoarthritis. Oncotarget. 2017;8(48):83563-9. doi: 10.18632/oncotarget.18745, PMID 29137364.
30. Georgiev T, Ivanova M, Kopchev A, Velikova T, Miloshov A, Kurteva E, et al. Cartilage oligomeric protein, matrix metalloproteinase-3, and Coll2-1 as serum biomarkers in knee osteoarthritis: a cross-sectional study. Rheumatol Int. 2018;38(5):821-30. doi: 10.1007/s00296-017-3887-y, PMID 29164307.
Copyright (c) 2025 Xiaowei Yang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.